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Aims. To establish a new model of zymosan-induced temporomandibular joint (TMJ) arthritis in the rat and to investigate
the role of nitric oxide. Methods. Inﬂammation was induced by an intra-articular injection of zymosan into the left TMJ.
Mechanical hypernociception, cell inﬂux, vascular permeability, myeloperoxidase activity, nitrite levels, and histological changes
were measured in TMJ lavages or tissues at selected time points. These parameters were also evaluated after treatment with the
nitric oxide synthase (NOS) inhibitors L-NAME or 1400W. Results. Zymosan-induced TMJ arthritis caused a time-dependent
leucocyte migration, plasma extravasation, mechanical hypernociception, and neutrophil accumulation between 4 and 24h.
TMJ immunohistochemical analyses showed increased inducible NOS expression. Treatment with L-NAME or 1400W inhibited
these parameters. Conclusion. Zymosan-induced TMJ arthritis is a reproducible model that may be used to assess both the
mechanismsunderlying TMJ inﬂammationand the potential tools fortherapies. Nitric oxide mayparticipate in the inﬂammatory
temporomandibular dysfunction mechanisms.
1.Introduction
Temporomandibular joint (TMJ) disorders are a group
of conditions that result in TMJ pain, which frequently
limits talking, chewing, and other basic daily activities with
high levels of pain-related disability [1]. Although these
conditions may be measured in terms of lost productivity
and human suﬀering, little is known about the under-
lying pathogenesis of temporomandibular disorder-related
pain.
Experimental models that allow the study of the mech-
anisms underlying these inﬂammatory and pain conditions
are of great clinical relevance. Rat models of TMJ inﬂam-
mation have been developed using intra-articular injections
of proinﬂammatory agents [2–17]. In this regard, zymosan,
a polysaccharide from yeast cell walls, produces a severe
and erosive synovitis [18, 19] associated with hyperalgesia
in animal models of knee arthritis [20]. This model has
been largely used in the study of knee arthritis, but to
o u rk n o w l e d g e ,n os t u d yh a su s e dz y m o s a nt oi n d u c eT M J
arthritis.
Nitric oxide (NO) is synthesized by nitric oxide synthase
(NOS) from L-arginine, and three isoforms of NOS have
been described. The endothelial (NOS1) and neuronal2 Journal of Biomedicine and Biotechnology
(NOS3) isoforms are constitutive, whereas NOS2 is the
inducible isoform (iNOS) [21]. The immunohistochemical
localizationofinducibleNOSinthesynovial tissueofhuman
TMJs has been demonstrated previously [22]. In addition,
an antinociceptive action of NO in the caudal part of
the spinal trigeminal nucleus during chronic carrageenan-
induced arthritis in rats TMJ has been described [23].
Despite this experimental evidence showing an involvement
of NO in TMJ arthritis, the role of the L-arginine:NO
system remains controversial. A striking therapeutic beneﬁt
with reduced signs and symptoms of erosive arthritis fol-
lowing the inhibition of NO production with nonspeciﬁc
NOS inhibitors has been observed [24]. However, selective
iNOSinhibitionexacerbatessynovialinﬂammation andjoint
degradation [25].
The aim of this study was to establish a new model of
zymosan-induced TMJ arthritis in the rat. Considering that
both the mediators involved in pain mechanisms during
inﬂammatory arthropathies and the exact role of NO in pain
development are still not fully deﬁned, we also aimed to
determinethetimecourseofvascularandcellulareventsthat
occur secondarily to zymosan-induced TMJ arthritis in rats
and the putative involvement of NO and neutrophils.
2.Materialsand Methods
2.1. Animals. Male Wistar rats (160–220g) were housed in
standard plastic cages with food and water available ad
libitum. They were maintained in a temperature-controlled
room (23 ± 2◦C) with a 12/12-hour light-dark cycle. All
experiments were designedtominimize animal suﬀeringand
to use the minimum number of animals required to achieve
a valid statistical evaluation. This study was conducted in
accordance with the Institutional Animal Care and Use
Committee of the Federal University of Cear´ a.
2.2. Induction of TMJ Arthritis. Rats were anesthetized with
tribromoethanol (1mL/100g, i.p.) and received an intra-
articular (i.art.) injection of 0.25, 0.5, 1, or 2mg zymosan
(40μL total volume) dissolved in sterile saline into the left
TMJ using a 30-gauge needle and 1-mL syringe. Sham
animals received saline i.art.
Before zymosan or saline injections, the TMJ skin region
was carefully shaved, the posteroinferior border of the zygo-
matic arch was palpated, and the needle was inserted inferior
to this point and advanced in a medial and anterior direction
until the needle made contact with the condyle. This contact
wasveriﬁedbythemovingofthemandible,andthepuncture
of the needle into the joint space was conﬁrmed by the
loss of resistance. Gentle aspiration ruled out intravascular
placement, after which the speciﬁed volume of zymosan
or saline was injected. To identify which dose of zymosan
would be used, animals were sacriﬁced at 6h after zymosan-
induced arthritis and both nociceptive (facial nociceptive
threshold) and inﬂammatory parameters (total cell counting
and myeloperoxidase assay) were evaluated.
2.3. Evaluation of Mechanical Hypernociception. Mechanical
hypernociception in the TMJ was evaluated by measuring
the threshold of force intensity that needed to be applied
to the TMJ region until the occurrence of a reﬂex response
of the animal (e.g., head withdrawal). The measurements
were performed by an examiner unaware of the treatments
and used a digital device (Insight, Ribeir˜ ao Preto, SP, Brazil)
that consisted of a rigid ﬁlament linked in an electronic
device that measured the response threshold in grams (g)
when the ﬁlament was applied to the surface of the tested
region. The facial areas to be tested around the TMJ were
carefully shaved, and the animals were put into individual
plastic cages 45min before the beginning of the tests. The
animals were submitted to a conditioning session of head
withdrawal threshold measurements in the testing room for
4 consecutive days under controlled temperatures (23 ±
2◦C) and low illumination. On the ﬁfth day, the basal force
threshold value was recorded (in triplicate) before the i.art.
injections of either zymosan or vehicle and after 2h, 4h, 6h,
12h, 24h, or 48h.
2.4. Synovial Fluid Collection and Cell Counting. Zymosan
injection (i.art) was performed in anesthetized rats. At
diﬀerent time points after zymosan-injections (2h, 4h, 6h,
12h, 24h, or 48h), the rats were sacriﬁced under anesthesia
and exsanguinated to analyze the responses at the required
time points. The superﬁcial tissues were dissected, and the
TMJ cavity was washed to collect the synovial ﬂuid (SF) by
a pumping and aspiration technique using 0.5mL of EDTA
in neutral buﬀered PBS. This procedure was repeated twice.
The total number of white cells in the synovial lavage ﬂuid
was counted using a Neubauerchamber.
2.5. Evans Blue Extravasation Measurement. Animals
received an i.v. injection of Evans blue dye (25mg/kg),
dissolved in saline, 30min before the times (e.g., 2h, 4h,
6 h ,1 2 h ,2 4 h ,o r4 8 h )a f t e rz y m o s a n - i n d u c e da r t h r i t i s .
Immediately after the extraction, the tissue was weighed and
placed in 2mL of formaldehyde overnight. The supernatant
(100μL) was extracted, and the absorbance at 630nm was
determined in spectrophotometer. The concentration was
determined by comparison to a standard curve of known
amounts of Evans blue dye in the extraction solution, which
was assessed within the same assay. The amount of Evans
blue dye (μg) was then calculated per mL of exudate [26].
2.6. Myeloperoxidase Activity Analysis. Myeloperoxidase
(MPO) is an enzyme found primarily in the azurophilic
granules of the neutrophils and has been used extensively
as a biochemical marker of granulocyte inﬁltration into
various tissues. The MPO activity assay measurement has
been described previously by bradley et al. [27]. In our
study, the MPO assay was conducted on the collected
synovial ﬂuid and in TMJ tissues at diﬀerent time points
after zymosan injection (2h, 4h, 6h, 12h, 24h, or 48h).
Brieﬂy, 100–200mg of TMJ tissue was homogenized in 1mL
of hexadecyltrimethylammonium bromide (HTAB) buﬀer
for each 50mg of tissue. The homogenate was centrifuged
at 4,500rpm for 12min at 4◦C. MPO activity in the
resuspended pellet was assayed by measuring the change inJournal of Biomedicine and Biotechnology 3
absorbance at 450nm using o-dianisidine dihydrochloride
and 1% hydrogen peroxide. The results are reported as the
MPO units/joint ﬂuid or unit/joint tissue. A unit of MPO
a c t i v i t yw a sd e ﬁ n e da st h ec o n v e r s i o no f1μmol of hydrogen
peroxide to water in 1min at 22◦C.
2.7. Determination of Nitric Oxide Production. The Griess
reaction was used as an indirect assay of NO production and
determined the total nitrite (NO2) and nitrate (NO3)a sa
measureofthedegreeofNOproduction.TotalNO2 andNO3
levels were determined after conversion of NO3 in the syn-
ovial exudate supernatants (0.08mL) to NO2 by incubation
with 0.01 mL nitrate reductase from an Aspergillus species
and 0.01 mL NADPH (1mM) for 30min at 37◦C. The NO2
levels were determined spectrophotometrically at 540nm by
comparing the absorbance of a 0.1mL sample after adding
0.1mL Griess reagent (sulfanilic acid (1%wv−1)a n dN - ( 1 -
naphythyl) ethylenediamine (0.1wv−1) in 5% phosphoric
acid to a NaNO2 (1–100mM) standard).
2.8. Histopathological Analysis. After sacriﬁce at 6h after
zymosan-induced arthritis, the TMJ was excised. The spec-
imens were ﬁxed in 10% neutral buﬀered formalin for
24h, demineralized in 10% EDTA, embedded in paraﬃn,
and sectioned along the long axis of the TMJ. Sections
of 5μm, which included the condyle, articular cartilage,
articular disc, synovial membrane, periarticular tissue, and
the skeletal muscle periarticular tissue, were evaluated under
light microscopy.
For the specimens processed for routine hematoxylin-
eosin (H & E) staining, histological analysis considered a 0–4
score grade based on the following parameters: cell inﬂux in
the synovial membrane (SM), cell inﬂux in the periarticular
tissue and in the skeletal muscle periarticular tissue, and the
thickness of synovial membrane.
2.9. Immunohistochemistry for iNOS. Immunohistochem-
istry for iNOS was performed using the streptavidin-biotin-
peroxidase method in formalin-ﬁxed, paraﬃn-embedded
tissue sections (5μm thick), mounted on poly-L-lysine-
coated microscope slides. The sections were deparaﬃnized
a n dr e h y d r a t e dt h r o u g hx y l e n ea n dag r a d e ds e r i e so f
alcohols. After antigen retrieval, endogenous peroxidase
was blocked (15min) with 3% (v/v) hydrogen peroxide,
and the sections were washed in phosphate-buﬀered saline
(PBS). Sections were incubated overnight (4◦C) with a
primary rabbit anti-iNOS antibody diluted 1:100 in PBS
plus bovine serum albumin (PBS-BSA). The slides were
then incubated with a biotinylated goat antirabbit anti-
body diluted 1:400 in PBS-BSA. After washing, the slides
wereincubatedwithanavidin-biotin-horseradish peroxidase
conjugate (Strep ABC complex, Vectastain ABC Reagent
and peroxidase substrate solution) for 30min according
to the Vectastain protocol. iNOS was visualized with the
chromogen 3,3 diaminobenzidine (DAB). Negative control
sections were processed simultaneously as described above
but with the ﬁrst antibody being replaced by 5% PBS-BSA.
None of the negative controls showed iNOS immunoreac-
tivity. Slides were counterstained with Harry’s hematoxylin,
dehydrated in a graded alcohol series, cleared in xylene, and
coverslipped.
2.10. Treatment. The NO inhibitors, L-NG-nitroarginine
methyl ester (L-NAME) (10, 30, or 100mg/kg, i.p.),
which is a nonselective NOS inhibitor, and N-[[3-
(aminomethyl)phenyl]methyl]-ethanimidamide (1400W)
(0.5 or 1mg/kg, s.c.), which is a selective iNOS inhibitor,
were used 30min before zymosan-induced arthritis.
Indomethacin (5mg/kg, s.c.) was used as a positive control
1hbeforezymosaninjection.
2.11. Statistical Analysis. The data are presented as the
means ± S.E.M. or medians, where appropriate. Diﬀerences
between means were compared using a one-way ANOVA
followed by the Bonferroni test. The Kruskal-Wallis test
followed by Dunn’s test was used to compare medians. A
probability value of P<. 05 indicated signiﬁcant diﬀerences.
3.Results
3.1. Dose Response and Time Course of Zymosan-Induced
TMJ Inﬂammation and Mechanical Hypernociception. The
dose response of zymosan-induced TMJ arthritis was ﬁrst
standardized and validated and was followed by a temporal
proﬁle assessment. Zymosan at 2mg was chosen, instead of
0.25, 0.5, or 1mg, because this dose was the only one that
changedboththenociceptivebehaviorandtheinﬂammatory
parameters.
Mechanical hypernociception induced by zymosan
started at 2h at all of the doses tested, although zymosan at
2mg showed a signiﬁcant reduction in mechanical threshold
during the 4th and 6thh compared to 0.25, 0.5, or 1mg
(Figure 1(a)). Furthermore, zymosan at 2mg signiﬁcantly
increased (P<. 05) the leukocyte count in the synovial ﬂuid
(Figure 1(b)), MPO activity in the TMJ ﬂuid (Figure 1(c)),
and MPO activity inthe TMJtissue (Figure 1(d))a tt h e6 t hh
after the induction of TMJ arthritis compared to the other
groups (Figures 1(b), 1(c),a n d1(d)).
The intra-articular (i.art.) 2-mg injection of zymosan
resulted in a time-dependent mechanical hypernociception
as measured by a clear decrease in the mechanical threshold
for head withdrawal (Figure 2(a)). This zymosan-induced
mechanical hypernociception started at the 2-hour time
point (P<. 05 versus Sham), peaked between 4h and 6h
(P<. 05 versus Sham), and lasted for up to 24h (P<. 05
versus Sham). In the intra-articular saline-injected animals
(Sham), no signiﬁcant changes in mechanical withdrawal
thresholds were observed at any time point.
A 2-mg injection of zymosan resulted in a signiﬁcant
increase in the number of polymorphonuclear cells. The
total leukocyte count showed that during the 4thh, an
inﬂux of leukocytes was initiated. The inﬂux of leukocytes
peaked during the 6thh and was maintained until the 12thh
(Figure 2(b))( P<. 05 versus Sham). This increase in
neutrophils was certiﬁed by the increase of MPO activity4 Journal of Biomedicine and Biotechnology
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Figure1:Inﬂammatoryandhypernociceptive dose-responseeﬀectofzymosan-inducedTMJarthritis.Zymosan(0.25,0.5,1,or2mg;40μL)
orsalinewasinjected i.art.intotheleftTMJoftherat.Themechanicalnociceptive thresholdwasmeasured beforeandafterani.art.injection
of zymosan or saline for 6 hours (a). Leukocyte migration was evaluated by cell counting in TMJ ﬂuid (b). MPO activity was evaluated in
TMJ ﬂuid (c) and TMJ tissues (d) for 6h after an i.art. injection of zymosanor saline. Data are expressed as means ± SEM (n = 6). ∗P<. 05
versus Sham. +P<. 05 versus 0.25, 0.5, and 1mg groups (ANOVA, Bonferroni).
both from the synovial lavage ﬂuid (Figure 2(c))a n dt h e
TMJ tissue (Figure 2(d))( P<. 05 versus Sham). MPO is
an enzyme found primarily in the azurophilic granules of
neutrophils. These changes were accompanied by plasma
extravasation that occurred in the TMJ during both the
4th and 6thh (Figure 2(e)) and peaked again at the 24thh
(P<. 05 versus Sham). The second phase of Evans blue dye
extravasation at 24h, which was not accompanied by MPO
activity, may be related to an endothelial barrier disruption
as described previously [28], but this hypothesis deserves
further investigation.
During the time course of zymosan TMJ arthritis devel-
opment, hypernociception was maximal at 4h of arthritis,
whereas cell inﬂux peaked at 6h. Based on these results, we
used these time points to assess the mechanisms underlying
TMJ inﬂammation and hypernociception.
3.2. Histopathological Analysis. In the 6thh after zymosan-
induced TMJ arthritis, an inﬂammatory cell inﬂux was
observed in the synovial membrane, the periarticular tissue,
the musculoskeletal tissue, and the thickness in synovial
membrane (Figures 3(b) and 3(c))c o m p a r e dt ot h eS h a m
group (Figure 3(a)). The cell types were predominantly
neutrophils,whichcharacterizedacuteinﬂammation. Edema
was also observed in the synovium (Figure 3(c)). Table 1
shows the scoresattributed to TMJ’s histopathological analy-
sis and compares the values between the Sham and zymosan
arthritic TMJ groups. A signiﬁcant (P<. 05) increase in
the inﬂammatory parameters was observed in the zymosan
group.
3.3. Eﬀects of L-NAME and 1400W. L-NAME (100mg/kg)
and 1400W (1mg/kg) signiﬁcantly reduced the mechanicalJournal of Biomedicine and Biotechnology 5
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Figure 2: Temporal proﬁle (0–48h) of the inﬂammatory and hypernociceptive eﬀects of zymosan-induced TMJ arthritis. Zymosan (2mg;
40μL) or saline was injected i.art. into the left TMJ of the rat. The mechanical nociceptive threshold was measured before and after an i.art.
injection of zymosan or saline until the 48th hour (a). Leukocyte migration was evaluated by cell counting in TMJ ﬂuid (b). MPO activity
from TMJ ﬂuid (c) and TMJ tissues (d). Plasma extravasation (PE) following an i.art. injection of zymosan or saline (e). Data are expressed
as means ± SEM (n = 6). ∗P<. 05 versus Sham (ANOVA, Bonferroni).6 Journal of Biomedicine and Biotechnology
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Figure 3: Photomicrographs of the histopathologicalanalysis of TMJ and periarticular tissues. Photomicrographs of TMJ and periarticular
tissues of nontreated (a, b, c) and L-NAME 100mg/kg or 1400W 1mg/kg treated animals (d, e). (a) Normalgroup TMJ (40x). (b) Arthritic
rats, TMJ induced by zymosan 2mg (40x) showing inﬂammatorycell inﬂux in the synovial membrane, periarticular tissue, musculoskeletal
tissue, and synovial membrane thickness. (c) Synovial tissue of arthritic rats injected with zymosan 2mg (400x) showing edema and
inﬂammatory cell inﬂux with polymorphonuclear predominance. (d) TMJ of arthritic rats injected with zymosan 2mg and treated with
L-NAME100mg/kg(40x).(e)TMJ ofarthriticratsinjected withzymosan2mgtreated with1400W1mg/kg(40x).C:condyle; AC:articular
cartilage;AD:articulardisc;SM:synovialmembrane;PAT:periarticulartissue;MET:musculoskeletaltissue.Hematoxylinandeosinstaining.
Table 1: Histopathologicalanalysis of TMJ: the eﬀects of nitric oxide synthase (NOS) inhibitors.
Cell inﬂux in the
synovial membrane
Synovial membrane
thickness Periarticular cell inﬂux Cell inﬂux in the
muscular tissue
Sham 0 (0-0) 0 (0-0) 0 (0-0) 0(0-0)
Zymosan 2.5 (1–3)∗ 3 (0–3)∗ 4 (4-4)∗ 3 (2–4)∗
L-NAME 100mg/kg 0.5 (0-1)+ 0 (0-0)+ 1 (0–2)+ 0 (0-0)+
1400W 1mg/kg 0 (0-0)+ 0 (0-0)+ 1 (0–2)+ 0 (0-0)+
∗P<. 05 versus Sham. +P<. 05 versus zymosan (Kruskal-Wallis,Dunn’s).
nociceptive thresholds (Figures 4(a) and 4(b)) during the
4thh after zymosan-induced TMJ arthritis (P<. 05
versus zymosan) and the leukocyte count (Figures 4(c) and
4(d)), MPO activity (Figures 4(e) and 4(f)), and plasma
extravasation (Figure 4(g)) during the 6thh after zymosan-
induced TMJ arthritis (P<. 05 versus zymosan). The
antinociceptive eﬀectsof indomethacin were similar to those
ofL-NAMEand the highest dose of1400W treatment. Inter-
estingly, the same results were observed when the cellular
inﬂux was assessed in joint ﬂuids. These results showed that
the administration of both NO blockers and indomethacin
inhibited nociception and inﬂammation in zymosan TMJ
arthritis, suggesting an involvement of multiple mechanisms
in zymosan-induced arthritis.
The histopathological analyses showed that L-NAME
(100mg/kg) (see Figure 3(d)) and 1400W (1mg/kg) (see
Figure 3(e)) reduced the inﬂammatory parameters to a
normal status with a lower inﬂammatory cell inﬂux in
the synovial membrane, the periarticular tissue, the mus-
culoskeletal tissue, and a lower thickness in the synovial
membrane. Table 1 shows the scores attributed to TMJ’s
histopathological analysis and compares the values between
the zymosan arthritic TMJ group, L-NAME (100mg/kg),
and 1400W (1mg/kg) groups. A signiﬁcant (P<. 05)
reduction in the inﬂammatory parameters was observed.
3.4. Immunohistochemical Analysis and Nitrite Levels in
Synovial Exudates. An immunohistochemical analysis for
iNOS showed an increase in iNOS expression, which was
characterized by brown-colored cells in arthritic TMJ rats
injected with zymosan (Figure 5(c)) compared to normal
animals (Figure 5(b)), which exhibited only a light expres-
sion of iNOS. The cell types that expressed iNOS were the
articular disc, articular cartilage chondrocytes, and synovial
cells. The negative control group sections were composed
of arthritic TMJ rats injected with zymosan that were not
treated with an anti-iNOS antibody (Figure 5(a)).
The amount of nitrite/nitrate detected in the joint
exudates, measured at the 6-hour time point after zymosan
(2mg, i.art.) administration, is shown in Figure 6.I n
rats whose joints were injected only with saline (Sham),
the nitrite concentrations in the joint exudates were low
and remained at these levels throughout the experimental
period.
4.Discussion
Experimental animal models of TMJ arthritis have been
proposed to study inﬂammation and pain conditions. Some
authors have suggested the induction of TMJ arthritis
surgically [29–32] or mechanically [33], using a systemicJournal of Biomedicine and Biotechnology 7
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Figure 4: Eﬀect of L-NAME and 1400W on the inﬂammatory and hypernociceptive eﬀects of zymosan in TMJ. Zymosan (2mg; 40μL) or
saline was injected i.art. into the left TMJ of the rat. L-NAME (100mg/kg) or 1400W (1mg/kg) was injected (i.p.) 30min before zymosan.
The mechanical nociceptive threshold was measured in L-NAME- (a) and 1400W-treated (b) animalsbefore and 4h after an i.art. injection
of zymosan or saline. After 6 h, leukocyte migration was evaluated in L-NAME- (c) and 1400W-treated (d) animals by cell counting in TMJ
ﬂuid. MPO activity from TMJ ﬂuid in L-NAME- and 1400W-treated animals (e). MPO activity in TMJ tissues in L-NAME- and 1400W-
treated animals (f). Plasma extravasation following an i.art. injection of zymosan or saline in L-NAME- and 1400W-treated animals (g).
Data are expressed as means ± SEM (n = 6). ∗P<. 05 versus Sham. +P<. 05 versus zymosan (ANOVA, Bonferroni).
(a) (b) (c)
Figure 5: Photomicrographs of the immunostaining for iNOS in the TMJ and periarticular tissues of zymosan-induced TMJ arthritis
in rats. (a) Negative control (sections in the absence of anti-iNOS antibody) of arthritic rats (100x). (b) Normal rat TMJ showing light
immunostaining for iNOS (100x). (c) TMJ arthritis induced by zymosan 2mg showing strong immunostaining for iNOS in chondrocytes
and synoviocytes (100x).
injection of heat-inactivated group A Streptococcus pyogenes
[34] or an injection in submandibular lymph nodes with
Mycobacterium cells [35]. However, other models consisting
of an intra-articular injection of inﬂammatory substances,
such as NaCI, KC1, histamine [2], mustard oil [3, 4],
substance P [5], heat-killed Mycobacterium butyricum in
paraﬃno i l[ 6], human recombinant IL-1α [7, 8], glutamate
[9], ovalbumin antigen [10], complete Freund’s adjuvant
[11, 12], formalin [13], capsaicin [14], or carrageenan [15–
17], have been used previously.
Zymosan has been used as a pro-inﬂammatory agent
f o rs o m et i m e[ 36]. To our knowledge, this is the ﬁrst
demonstration of a zymosan-induced arthritis in the TMJ.
Acute rat knee joint zymosan arthritis is characterized by an
increase in vascular permeability, cell migration, and pain.
Later, a progressive synovitis occurs with mononuclear cellJournal of Biomedicine and Biotechnology 9
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Figure 6: Nitrite levels in synovial exudates of zymosan-induced
TMJ arthritis. Zymosan was injected i.art. and the NO release in
exudates (as NO2
− /NO3
−) was measured 6 h after zymosan. Sham
animals received only saline i.art. Injection of saline into the joints
did not increase NO release throughout the experiment. Data are
expressed asmeans±SEM(n = 6). ∗P<. 05versusSham(ANOVA,
Bonferroni).
inﬁltration and a ﬁbroblast reaction [18–20]. Our group has
also demonstrated articular cartilage and subchondral bone
degradationduringthechronicstages ofzymosan arthritis in
the rat knee joint [24].
A zymosan 2-mg, but not saline, injection into the
TMJ induced hypernociception, leukocyte inﬂux, high MPO
activity, and Evans blue dye extravasation, which was similar
to the eﬀects of zymosan rat knee joint arthritis [20,
24]. The TMJ mechanical hypernociceptive response was
accompanied by neutrophil inﬂux as demonstrated by the
leukocytecell count and MPO activity. Similarly, in zymosan
rat knee joint arthritis, neutrophils contribute to acute joint
hyperalgesia [37].
In a model of zymosan-induced sciatic inﬂammatory
neuritis, both low and high doses of zymosan produce terri-
torial hypernociception. However, only the higher zymosan
dose is associated with an increased release of interleukin-1,
tumornecrosis factor, and reactive oxygenspecies from peri-
sciatic immune cells [38]. These data support the argument
that low doses of zymosan in the TMJ promoted hyper-
nociception, although it was not associated with immune
cell activation. In the present work, zymosan at 2mg was
chosen instead of 0.25, 0.5, or 1mg because this dose was
the only one able to change both the nociceptive behavior
and the inﬂammatory parameters. Furthermore, considering
that the hypernociception was maximal during the 4thh of
arthritis but the cellular inﬂux peaked during the 6thh, we
used these time points to assess the mechanisms underlying
TMJ inﬂammation and the potential tools for therapy.
Regarding the inﬂammatory parameters, the histological
features correlated to the increase in leukocyte inﬂux, high
MPO activity, and Evans blue dye extravasation, which
showed an acute inﬂammation in the synovial membrane,
the periarticular tissue, and the musculoskeletal tissue, with
a predominance of neutrophils in the inﬂammatory cell
inﬁltrate. Edema and a thickness in the synovial mem-
brane were also observed. Other studies have evaluated
TMJ histopathology [3, 35, 39, 40]; however, ours is the
ﬁrst study to describe the histopathological inﬂammatory
parameters involving the articular and periarticular tissues
in an experimental TMJ arthritis.
A large number of inﬂammatory and signaling sub-
stances have been suggested to play a role in joint
inﬂammatory disorders. Among these, NO, a free oxygen
radical from the L-arginine:NO system, is an important
factor in immunological, inﬂammatory, and nociceptive
processes, although its participation is still controversial in
the inﬂammatory process [21]. Endogenous NO is analgesic,
whereas exogenously administered NO provokes pain [41,
42]. More recently, it was shown that the NO donor 3-
morpholinosydnonimine (SIN-1) produces either analgesia
or nociception in rats, depending on the dose and the pain
model used [43]. In the zymosan arthritis model in the rat
knee joints, our group has demonstrated previously that NO
donors,SIN-1andsodiumnitroprusside,displayanalgesiain
ongoing pain, revealing an intrinsic antinociceptive activity
[44].
Within inﬂamed joints, a plethora of cells are potential
sources of NO, including synoviocytes, chondrocytes, and
mast cells, as well as inﬁltrating neutrophils and monocytes
[37]. In the present study, increased nitrite/nitrate levels, an
index of NO formation, were detected in the arthritic TMJ
exudates. Also, histopathological analyses of immunohisto-
chemical stains showed an increase in iNOS expression in
thearticulardiscandarticularcartilagechondrocytesandthe
synovial cells of zymosan arthritic TMJ. Similarly, iNOS is
observed in the TMJ synovial membrane in cases of internal
derangement and TMJ arthritis [22]a n dt h ea c t i v a t i o no f
iNOS is evidently important in inﬂammatory arthritis [24].
Our results revealed that iNOS was present in the
articular disc, the articular cartilage chondrocytes, and the
synovial cells of the rat TMJ under physiological conditions.
Immunoelectron microscopyhas revealedthat immunoreac-
tiveiNOSisfoundinbothsynoviocytestypeA(macrophage-
like) and B (ﬁbroblast-like) [45]. NO may play an important
role in the physiological maintenance of the TMJ.
In the present study, NOS inhibitors, L-NAME and
1400W, demonstrated anti-inﬂammatory eﬀects associated
with a reduction ofmechanical hypernociception.NOSinhi-
bition was associated with a signiﬁcant decrease in leukocyte
inﬂux, MPO activity, and plasma extravasation in TMJ
exudates. In accordance with these data, histopathological
changes were mainly observed as a signiﬁcant reduction
of edema, cellular inﬂux, and synovial hyperplasia. Our
group has previously demonstrated that the use of both
nonselective and selective iNOS inhibitors causes a general
anti-inﬂammatory eﬀectin zymosan-induced arthritis inthe
rat knee joint [24]. In the carrageenan TMJ arthritis model,
neuronal nitric oxide synthase (nNOS) immunoreactivity
and mRNA expression are stable during arthritis evolution,
but its activity signiﬁcantly increases during the chronic
phases, supporting an antinociceptive role of nNOS as
evidenced by pain threshold experiments [23].10 Journal of Biomedicine and Biotechnology
5.Conclusion
In the present study, we demonstrated that a 2-mg injection
of zymosan into the rat TMJ was a very robust experimental
model for the study of TMJ disorders, which are often asso-
ciated with spontaneous pain and subsequent eﬀects, such
as secondary hyperalgesia, allodynia, and referred pain. We
showed that our animal model resulted in an inﬂammatory
response, which was characterized by leukocyte inﬁltration,
increased plasma extravasation and NO levels, iNOS TMJ
tissue expression, and mechanical hypernociception. In
this model, even if the parameters studied are normal
or reduced by drug interactions, the TMJ pain can be
measured non-invasively. In this regard, the administration
of both nonselective and selective iNOS inhibitors was
antinociceptive and anti-inﬂammatory in TMJ zymosan
arthritis. The involvementofmultiple mechanisms related to
painful process associated with TMJ arthritis is indicative of
theneedforfurtherinvestigationsthatmayleadtothedesign
of therapeuticalternatives for the treatment of inﬂammatory
arthropathies.
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